Portal Hypertension - 2018 Pipeline Insights: Cumberland Pharmaceuticals and Conatus Pharmaceuticals Dominate the Market - ResearchAndMarkets.com

DUBLIN--()--The "Portal Hypertension- Pipeline Insights, 2018" report has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present scenario and growth prospects across Portal Hypertension.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

This report provides detailed analysis of 3+ active products along with 3+ companies involved. Cumberland Pharmaceuticals and Conatus Pharmaceuticals are among the major drug developers as per the current pipeline scenario.

Products covered by Phase

  • Phase II
  • Unknown Stage
  • Inactive (Dormant and Discontinued)

Overview of pipeline development activities for Portal Hypertension

  • Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
  • Therapeutic segmentation of products for Portal Hypertension
  • The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Scope

  • Provides an overview of therapeutic pipeline activity for Portal Hypertension across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Portal Hypertension therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Portal Hypertension

Key Topics Covered

  1. Executive Summary
  2. Disease Overview
  3. Introduction
  4. Causes
  5. Pathophysiology
  6. Symptoms
  7. Diagnosis
  8. Management and Treatment
  9. Pipeline Therapeutics (Active Products)
  10. Pipeline Therapeutics (Inactive Products)
  11. Comparative Analysis
  12. Mid Stage Products (Phase II)
  13. Comparative Analysis
  14. Ifetroban: Cumberland Pharmaceuticals
  15. Product Description
  16. Research and Development
  17. Product Development Activities
  18. The list continues..
  19. Unknown Stage Products
  20. Comparative Analysis
  21. Therapeutic Assessment: Active Products
  22. Assessment by Stage and Product Type
  23. Assessment by Route of Administration
  24. Assessment by Stage and Route of Administration
  25. Assessment by Molecule Type
  26. Assessment by Stage and Molecule Type
  27. Inactive Products
  28. Comparative Analysis
  29. Appendix

Companies Featured

  • Adare Pharmaceuticals
  • Conatus Pharmaceuticals
  • Cumberland Pharmaceuticals
  • Ferring Pharmaceuticals
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Mallinckrodt Pharmaceuticals
  • Mezzion Pharma
  • Novartis
  • ONO Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/sqm5rr/portal?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs